UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 2, 2007
Date of Report (Date of Earliest Event Reported)
ALLERGAN, INC.
(Exact Name of Registrant as Specified in its Charter)
| |
|
|
|
|
Delaware
(State of Incorporation)
|
|
1-10269
(Commission File Number)
|
|
95-1622442
(IRS Employer
Identification Number) |
2525 Dupont Drive
Irvine, California 92612
(Address of Principal Executive Offices) (Zip Code)
(714) 246-4500
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 2.02. Results of Operations and Financial Condition.
On May 2, 2007, Allergan, Inc. (“Allergan”) issued a press release announcing operating
results for the first quarter ended March 30, 2007. In its press release, Allergan included
non-GAAP financial measures, as defined in Regulation G promulgated by the SEC. A copy of the
press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
This information and the information contained in the press release shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section. The information in this Current Report is not
incorporated by reference into any filings of Allergan made under the Securities Act of 1933, as
amended, whether made before or after the date of this Current Report, regardless of any general
incorporation language in the filing unless specifically stated so therein.
Item 8.01. Other Events.
In the press release discussed in Item 2.02 above, Allergan also announced that its Board of
Directors has declared a 2-for-1 stock split of Allergan common stock, to be effected in the form
of a stock dividend. Stockholders of record at the close of business on June 11, 2007 will receive
one additional share of Allergan common stock for each share held on that date. The new shares of
Allergan common stock will be distributed on June 22, 2007.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 |
|
Allergan, Inc. press release dated May 2, 2007 |